What Happens to Fat vs. Muscle When You Lose Weight on Tirzepatide
About 75% of the weight lost on tirzepatide was fat and 25% was lean mass — the same ratio seen with placebo, just at a much larger scale.
Quick Facts
What This Study Found
Tirzepatide produced a 21.3% reduction in total body weight at 72 weeks, composed of a 33.9% loss in fat mass and a 10.9% loss in lean mass. In the placebo group, these figures were 5.3%, 8.2%, and 2.6% respectively (p < 0.001 for all comparisons).
Critically, the composition of weight lost was approximately 75% fat mass and 25% lean mass in both the tirzepatide and placebo groups. This ratio remained consistent across subgroups defined by sex, age, baseline BMI, and baseline fat mass.
Key Numbers
How They Did This
This was a substudy of 160 participants from the larger SURMOUNT-1 randomized controlled trial (2,539 total). Participants had obesity or overweight and underwent dual-energy X-ray absorptiometry (DXA) body scans at baseline and at week 72. Results were pooled across tirzepatide doses (5, 10, and 15 mg) and compared with placebo. Post hoc subgroup analyses examined consistency across sex, age, BMI, and baseline fat mass categories.
Why This Research Matters
A major concern with GLP-1 and dual-agonist weight loss drugs is that people may lose too much muscle along with fat. This study provides reassurance that tirzepatide's weight loss follows the typical biological pattern — about three-quarters fat, one-quarter lean mass — rather than causing disproportionate muscle wasting. The consistency of this ratio across subgroups strengthens the finding.
The Bigger Picture
As tirzepatide and similar drugs become widely used for obesity, understanding what type of tissue is being lost is essential. This body composition data from SURMOUNT-1 helps answer one of the most frequently asked questions about these medications and informs clinical guidance around exercise and protein intake during treatment.
What This Study Doesn't Tell Us
The substudy included only 160 of the 2,539 SURMOUNT-1 participants, which may not be fully representative. Tirzepatide doses were pooled, so dose-specific effects on body composition could not be assessed. The study did not evaluate whether lean mass loss impacted physical function, strength, or metabolic rate. DXA measures total lean mass, which includes water and organs — not just skeletal muscle.
Questions This Raises
- ?Does the lean mass lost on tirzepatide include clinically meaningful muscle loss, or is much of it water and organ mass?
- ?Would resistance training during tirzepatide treatment shift the ratio to preserve more lean mass?
- ?Do body composition outcomes differ at the individual tirzepatide dose levels (5 mg vs. 10 mg vs. 15 mg)?
Trust & Context
- Key Stat:
- 75% fat / 25% lean The ratio of fat-to-lean mass loss was consistent across tirzepatide and placebo groups and across all subgroups analyzed
- Evidence Grade:
- This is a substudy from a Phase 3 randomized, double-blind, placebo-controlled trial (SURMOUNT-1) using objective DXA body scans, giving it strong methodological rigor, though the substudy sample was relatively small.
- Study Age:
- Published in 2025, this is current and highly relevant as tirzepatide use continues to expand for obesity treatment.
- Original Title:
- Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.
- Published In:
- Diabetes, obesity & metabolism, 27(5), 2720-2729 (2025)
- Authors:
- Look, Michelle(2), Dunn, Julia P(7), Kushner, Robert F(4), Cao, Dachuang, Harris, Charles, Gibble, Theresa Hunter, Stefanski, Adam, Griffin, Ryan
- Database ID:
- RPEP-12292
Evidence Hierarchy
Frequently Asked Questions
Does tirzepatide cause you to lose more muscle than fat?
No. About 75% of the weight lost on tirzepatide was fat and 25% was lean mass, which is the same ratio seen with placebo and is typical for weight loss in general.
Was the body composition effect different for men versus women?
The 75/25 fat-to-lean ratio remained consistent across subgroups including sex, age, baseline BMI, and starting fat mass, suggesting the pattern holds broadly.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-12292APA
Look, Michelle; Dunn, Julia P; Kushner, Robert F; Cao, Dachuang; Harris, Charles; Gibble, Theresa Hunter; Stefanski, Adam; Griffin, Ryan. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.. Diabetes, obesity & metabolism, 27(5), 2720-2729. https://doi.org/10.1111/dom.16275
MLA
Look, Michelle, et al. "Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.." Diabetes, 2025. https://doi.org/10.1111/dom.16275
RethinkPeptides
RethinkPeptides Research Database. "Body composition changes during weight reduction with tirzep..." RPEP-12292. Retrieved from https://rethinkpeptides.com/research/look-2025-body-composition-changes-during
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.